Limbix, a Palo Alto, CA-based developer of digital therapeutics for the treatment of adolescent mental health disorders, raised $9M in Series A funding.
The round was led by GSR Ventures, with participation from existing investors Sequoia Capital, Storm Ventures, NextGen Venture Partners, and BIXINK Therapeutics.
The company intends to use the funds for research and development of its flagship product, Limbix Spark, the first prescription digital therapeutic designed to treat adolescents with depression.
Led by Ben Lewis, CEO and co-founder, Limbix is a prescription digital therapeutic company advancing Limbix Spark, a multi-week cognitive behavioral therapy based program focused on the completion of value-based activities that spark feelings of pleasure or mastery. Once FDA cleared, it will be available as a new treatment option for pediatricians to prescribe to their patients.